GlobeNewswire Inc.··Novo Nordisk A/SNovo Nordisk Wins EU Nod for Wegovy 7.2mg Pen, Oral GLP-1 Alternative
EMA's CHMP recommends approval of Novo Nordisk's Wegovy 7.2mg pen and oral semaglutide pill for obesity treatment, with Q3 2026 EU launch anticipated.
NVOCHMP approvalweight loss